A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Molecular & Pharmacological Approach for the Optimisation of Combination Therapy of a Long-acting β2 Agonist and a Corticosteroid in Chronic Obstructive Pulmonary Disease
2011
Combination inhalers of long-acting β2 agonists (LABAs) with inhaled corticosteroids (ICSs) are now widely used for the treatment of asthma. However, corticosteroid (CS) insensitivity can be a major barrier for the treatment of chronic obstructive pulmonary disease (COPD). Existing ICSs are less beneficial on the decline of lung function in the long term. Even at the cellular level, CSs are less effective in primary cells, peripheral blood mononuclear cells (PBMCs) obtained from COPD patients
doi:10.25560/6881
fatcat:vim6g6ih3rhvbnoxlcfqfayqq4